ArticleAnnals of surgical oncology2019
Defining Tumor Rupture in Gastrointestinal Stromal Tumor.
Article in Annals of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial.British journal of cancer · 2024Trial
- Prediction of the mitotic index and preoperative risk stratification of gastrointestinal stromal tumors with CT radiomic features.La Radiologia medica · 2023Trial
- Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features.La Radiologia medica · 2022Trial
- Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.JAMA surgery · 2020Trial
- Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025).Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Review
- Adjuvant treatment of gastrointestinal stromal tumors (GIST)-state of the art, controversies, and future directions.ESMO gastrointestinal oncology · 2026Review
- Surgical Approaches for Primary Gastric GIST After the Introduction of Robotic Surgery: A 10-Year Single-Center Experience.Cancers · 2026Article
- A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry study.Experimental and therapeutic medicine · 2026Article
- A Rare Case of Multifocal Ileal and Mesenteric Gastrointestinal Stromal Tumors With Spontaneous Rupture.Cureus · 2026Article
- Article
- Review
- Beyond Laparotomy: Multimodal Strategies and Emerging Evidence in Minimally Invasive Management of Gastric Gastrointestinal Stromal Tumors.BioMed research international · 2026Review
- Approach to Gastric Subepithelial Lesions: From Differential Diagnosis to Histologic Confirmation.The Korean journal of helicobacter and upper gastrointestinal research · 2025Review
- Laparoscopic surgical approaches for various locations of gastrointestinal stromal tumours.World journal of clinical cases · 2025Review
- What kind of tumour rupture requires adjuvant therapy?British journal of cancer · 2024Article
- [Gastrointestinal stromal tumors : Where do we stand?]Pathologie (Heidelberg, Germany) · 2024Review
- Pan-Canadian consensus recommendations for GIST management in high- and low-throughput centres across Canada.Therapeutic advances in medical oncology · 2024Review
- Factors associated with gastrointestinal stromal tumor rupture and pathological risk: A single-center retrospective study.World journal of radiology · 2023Article
- Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GISTs) is Effective and Safe: Results from a Prospective Single-Center Study with 108 Patients.Annals of surgical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tumor rupture is an important risk factor predictive of recurrence after macroscopically complete resection of gastrointestinal stromal tumors (GISTs), and an indication for defined interval or even lifelong adjuvant therapy with imatinib according to guidelines. However, there is no consensus or universally accepted definition of the term 'tumor rupture', and, consequently, its incidence varies greatly across reported series. Without predefined criteria, the clinical significance of rupture has also been difficult to assess on multivariate analysis of retrospective data. We reviewed the relevant literature and international guidelines, and, based on the Oslo criteria, proposed the following six definitions for 'tumor rupture': (1) tumor fracture or spillage; (2) blood-stained ascites; (3) gastrointestinal perforation at the tumor site; (4) microscopic infiltration of an adjacent organ; (5) intralesional dissection or piecemeal resection; or (6) incisional biopsy. Not all minor defects of tumor integrity should not be classified as rupture, i.e. mucosal defects or spillage contained within the gastrointestinal lumen, microscopic tumor penetration of the peritoneum or iatrogenic damage only to the peritoneal lining, uncomplicated transperitoneal needle biopsy, and R1 resection. This broad definition identifies GIST patients at particularly high risk of recurrence in population-based cohorts; however, its applicability in other sarcomas has not been investigated. As the proposed definition of tumor rupture in GIST has limited evidence based on the small number of patients with rupture in each retrospective study, we recommend validating the proposed definition of tumor rupture in GIST in prospective studies and considering it in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.